Invion Ltd (IVX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.163x

Based on the latest financial reports, Invion Ltd (IVX) has a cash flow conversion efficiency ratio of -0.163x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.34 Million ≈ $-951.19K USD) by net assets (AU$8.25 Million ≈ $5.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Invion Ltd worth for the company's overall valuation and market capitalisation.

Invion Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Invion Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Invion Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Invion Ltd ranked by their cash flow conversion efficiency. Explore Invion Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Curis Inc
NASDAQ:CRIS
-0.708x
Global Battery Metals Ltd
V:GBML
-0.020x
Vast Renewables Limited Ordinary Shares
NASDAQ:VSTE
0.148x
Tarachi Gold Corp
F:4RZ
-0.031x
GENETIC ANALYSIS NK -60
F:8V8
-0.218x
Kestrel Gold Inc
V:KGC
-0.035x
Nanocap Group AB Series B
ST:NANOC-B
N/A
Mulberry Group PLC
LSE:MUL
-0.265x

Annual Cash Flow Conversion Efficiency for Invion Ltd (2006–2025)

The table below shows the annual cash flow conversion efficiency of Invion Ltd from 2006 to 2025. View IVX stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$8.25 Million
≈ $5.84 Million
AU$-2.97 Million
≈ $-2.10 Million
-0.360x -116.34%
2024-06-30 AU$14.44 Million
≈ $10.22 Million
AU$-2.40 Million
≈ $-1.70 Million
-0.166x -68.80%
2023-06-30 AU$18.40 Million
≈ $13.02 Million
AU$-1.81 Million
≈ $-1.28 Million
-0.099x -73.98%
2022-06-30 AU$19.58 Million
≈ $13.85 Million
AU$-1.11 Million
≈ $-784.62K
-0.057x -164.92%
2021-06-30 AU$4.79 Million
≈ $3.39 Million
AU$417.98K
≈ $295.74K
0.087x +410.95%
2020-06-30 AU$5.43 Million
≈ $3.84 Million
AU$-152.47K
≈ $-107.88K
-0.028x +92.73%
2019-06-30 AU$5.46 Million
≈ $3.86 Million
AU$-2.11 Million
≈ $-1.49 Million
-0.386x -531.44%
2018-06-30 AU$7.91 Million
≈ $5.59 Million
AU$707.09K
≈ $500.31K
0.089x +245.01%
2017-06-30 AU$4.01 Million
≈ $2.84 Million
AU$-247.14K
≈ $-174.87K
-0.062x +90.36%
2016-06-30 AU$5.99 Million
≈ $4.24 Million
AU$-3.83 Million
≈ $-2.71 Million
-0.640x +56.67%
2015-06-30 AU$6.86 Million
≈ $4.85 Million
AU$-10.13 Million
≈ $-7.17 Million
-1.477x -244.59%
2014-06-30 AU$10.16 Million
≈ $7.19 Million
AU$-4.35 Million
≈ $-3.08 Million
-0.429x -36.75%
2013-06-30 AU$11.04 Million
≈ $7.81 Million
AU$-3.46 Million
≈ $-2.45 Million
-0.313x +82.26%
2012-06-30 AU$6.01 Million
≈ $4.25 Million
AU$-10.62 Million
≈ $-7.51 Million
-1.766x -128.12%
2011-06-30 AU$-2.14 Million
≈ $-1.52 Million
AU$-13.46 Million
≈ $-9.52 Million
6.281x +97.36%
2010-06-30 AU$-4.78 Million
≈ $-3.38 Million
AU$-15.20 Million
≈ $-10.76 Million
3.182x +4.10%
2008-06-30 AU$-3.23 Million
≈ $-2.28 Million
AU$-9.86 Million
≈ $-6.98 Million
3.057x +117.84%
2007-06-30 AU$715.28K
≈ $506.11K
AU$-12.26 Million
≈ $-8.67 Million
-17.134x -597.95%
2006-06-30 AU$4.83 Million
≈ $3.42 Million
AU$-11.87 Million
≈ $-8.40 Million
-2.455x --

About Invion Ltd

AU:IVX Australia Drug Manufacturers - Specialty & Generic
Market Cap
$2.36 Million
AU$3.34 Million AUD
Market Cap Rank
#29894 Global
#1733 in Australia
Share Price
AU$0.04
Change (1 day)
-13.33%
52-Week Range
AU$0.03 - AU$0.11
All Time High
AU$4.80
About

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more